Country: Canada
Language: English
Source: Health Canada
SPESOLIMAB
BOEHRINGER INGELHEIM (CANADA) LTD LTEE
L04AC22
SPESOLIMAB
60MG
SOLUTION
SPESOLIMAB 60MG
INTRAVENOUS
15G/50G
Prescription
Active ingredient group (AIG) number: 0164521001; AHFS:
APPROVED
2023-03-22
_Product Monograph _ _ _ _Spevigo (spesolimab) _ _Page 1 of 21_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr SPEVIGO® spesolimab for injection Concentrate for solution for intravenous infusion 450 mg/7.5 mL (60 mg/mL) Interleukin-36 Inhibitor ATC code: L04AC22 Boehringer Ingelheim (Canada) Ltd. 5180 South Service Road Burlington, Ontario L7L 5H4 www.boehringer-ingelheim.ca Date of Initial Authorization: MAR 22, 2023 Submission Control Number: 267362 BICL #0174-01 Spevigo® is a registered trademark of Boehringer Ingelheim International GmbH, used under license. _ _ _Product Monograph _ _ _ _Spevigo (spesolimab) _ _Page 2 of 21_ TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . TABLE OF CONTENTS ............................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS ............................................................................................................. 4 1.1 Pediatrics (<18 years of age) .................................................................................... 4 1.2 Geriatrics (≥65 years of age) .................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................ 4 4 DOSAGE AND ADMINISTRATION ................................................................................ 4 4.1 Dosing Considerations ............................................................................................. 4 4.2 Recommended Dose and Dosage Adjustment ........................................................ 4 4.3 Reconstitution .......................................................................................................... 5 4.4 Administration ....................................................................... Read the complete document